Dyslipidémie
.webp/jcr:content/Cardio2_cover%20(2).webp)
Articles
Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice
A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.
Why choose PRALUENT®?
The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.2
Éducation
%20(1).png)
Vidéo éducative sur le carcinome épidermoïde cutané : Docteur Rauh - oncologue médical CHEM Luxembourg
.jpg/jcr:content/image%20(24).jpg)
.jpg/jcr:content/image%20(81).jpg)
Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi
A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I
Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262
.svg)
.svg)
